XNASTLSA
Market cap84mUSD
Jan 16, Last price
0.76USD
1D
-3.50%
1Q
-13.54%
IPO
-54.49%
Name
Tiziana Life Sciences Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-17.52%
Rev. gr., 5y
%
Revenues
0k
Net income
-18m
L+9.15%
CFO
-16m
L-19.97%
Profile
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 8,113 | 14,637 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (8,113) | (14,637) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 449 | 811 | |||||||
Tax Rate | |||||||||
NOPAT | (8,562) | (15,448) | |||||||
Net income | (17,691) 9.15% | (16,208) -30.79% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 24 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 138 | 122 | |||||||
Long-term debt | 356 | 608 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (5,243) | (19,198) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (15,698) | (19,615) | |||||||
CAPEX | |||||||||
Cash from investing activities | (1,253) | (3,996) | |||||||
Cash from financing activities | 40 | (55) | |||||||
FCF | (8,466) | (15,518) | |||||||
| Balance | |||||||||
Cash | 1,183 | 18,122 | |||||||
Long term investments | 4,554 | 1,806 | |||||||
Excess cash | 5,737 | 19,928 | |||||||
Stockholders' equity | (16,512) | (592) | |||||||
Invested Capital | 22,295 | 20,528 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 101,526 | ||||||||
Price | 0.56 -6.43% | 0.60 -37.66% | |||||||
Market cap | 60,764 -35.37% | ||||||||
EV | 41,566 | ||||||||
EBITDA | (8,017) | (14,586) | |||||||
EV/EBITDA | |||||||||
Interest | 10 | 7 | |||||||
Interest/NOPBT | |||||||||